HC Wainwright Forecasts Strong Price Appreciation for Liquidia (NASDAQ:LQDA) Stock

Liquidia (NASDAQ:LQDA) had its price target upped by investment analysts at HC Wainwright from $50.00 to $55.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 59.33% from the company’s previous close. HC Wainwright also issued estimates for Liquidia’s Q4 2025 earnings at $0.33 EPS, FY2025 earnings at ($0.64) EPS, Q1 2026 earnings at $0.43 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.86 EPS, Q4 2026 earnings at $0.98 EPS, FY2026 earnings at $2.89 EPS, FY2027 earnings at $2.97 EPS, FY2028 earnings at $4.97 EPS, FY2029 earnings at $7.57 EPS and FY2030 earnings at $9.85 EPS.

A number of other analysts also recently weighed in on LQDA. BTIG Research reissued a “buy” rating and issued a $49.00 price target on shares of Liquidia in a report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating and set a $52.00 price target on shares of Liquidia in a research note on Wednesday, February 25th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday. Finally, Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a research report on Sunday, January 18th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $40.56.

Liquidia Price Performance

NASDAQ LQDA opened at $34.52 on Friday. The stock has a 50-day simple moving average of $37.07 and a 200 day simple moving average of $30.84. Liquidia has a twelve month low of $11.26 and a twelve month high of $46.67. The stock has a market capitalization of $3.00 billion, a PE ratio of -23.97, a P/E/G ratio of 0.60 and a beta of 0.52. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.18). Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The business had revenue of $92.02 million during the quarter. The company’s quarterly revenue was up 3072.4% compared to the same quarter last year. Research analysts anticipate that Liquidia will post -1.51 EPS for the current year.

Insider Buying and Selling

In other Liquidia news, CEO Roger Jeffs sold 66,610 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $2,493,212.30. Following the sale, the chief executive officer directly owned 1,037,528 shares in the company, valued at $38,834,673.04. This represents a 6.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Jason Adair sold 688 shares of the stock in a transaction on Monday, January 26th. The stock was sold at an average price of $41.65, for a total value of $28,655.20. Following the transaction, the insider owned 211,169 shares of the company’s stock, valued at $8,795,188.85. This represents a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 212,534 shares of company stock worth $7,964,719. Insiders own 26.50% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Several large investors have recently made changes to their positions in LQDA. Farallon Capital Management LLC increased its position in shares of Liquidia by 1.1% during the 4th quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after purchasing an additional 90,400 shares in the last quarter. Vanguard Group Inc. boosted its position in Liquidia by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock valued at $138,439,000 after buying an additional 52,671 shares in the last quarter. Opaleye Management Inc. grew its stake in Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after buying an additional 215,000 shares during the last quarter. Caprock Group LLC increased its holdings in shares of Liquidia by 9.3% during the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after buying an additional 151,832 shares in the last quarter. Finally, TCG Crossover Management LLC acquired a new stake in shares of Liquidia during the third quarter worth approximately $38,887,000. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reported robust YUTREPIA uptake, $148.3M net product sales for 2025, $90.1M in Q4, a second consecutive profitable quarter and $190.7M cash — a clear commercialization win that supports longer-term revenue visibility. Read More.
• Positive Sentiment: HC Wainwright materially raised multi-year earnings forecasts (FY2026–FY2029) and lifted near-term Q4 estimates — analyst bullishness can underpin upside as sell-side models shift higher. Read More.
• Neutral Sentiment: Transcript and call highlights show management emphasizing rapid prescriber adoption, plans to expand the sales force and fund development from operations — useful context for investors but not an immediate catalyst. Read More.
• Neutral Sentiment: Market commentary and valuation pieces weigh whether the post-launch run-up leaves room for further gains; this shapes investor positioning (buyers vs. profit-takers). Read More.
• Negative Sentiment: Shares gapped down in pre-market trading after the quarter amid perceptions the $0.15 EPS print failed to meet some consensus targets; that short-term disappointment drove selling pressure. Read More.
• Negative Sentiment: Despite strong sales, reporting differences vs. certain consensus figures (and a mixed presentation of GAAP vs. non‑GAAP metrics) created confusion and volatility around the print. Read More.
• Negative Sentiment: Notable insider and institutional selling (Quiver/SEC filings) and a reported $5.1M manager sale add near-term supply pressure and may weigh on sentiment until clearer follow-through from sales growth. Read More. Read More.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).